Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M
Department of Endocrinology, Tbilisi State Medical University.
Georgian Med News. 2007 Apr(145):52-5.
To investigate the relative role of the adiponectin and leptin in the insulin resistance (IR) and obesity we studied plasma levels of these adipocytokines in obese and insulin resistant postmenopausal (PM) females with type 2 diabetes (DM2) during 6 months of Metformin therapy. We recruited 26 PM women, between the ages of 50 and 67 (59,7+/-8,1 years). These women had a BMI of 36,6+/-1,8 kg/m2. After baseline measurements Metformin therapy has been initiated (1700+/-2550 mg per day). Duration of therapy was 6 months. The results of investigations of adipocytokines after Metformin 6 months therapy shown that circulating adiponectin levels were significantly increased (19,1+/-6,0 vs. 16,1+/-3,9 ng/ml, p=0,008) together with significant reduction of BMI (35,9+/-1,9 vs. 36,6+/-1,8 kg/m2, p=0,005) and IR (3,05+/-0,89 vs. 3,96+/-0,70, p<0,001). The magnitude of the change in adiponectin levels positively correlated with the magnitude of BMI reduction (r=0,4784, p=0,013) and IR reduction (r=0,5779, p=0,002). Any significant correlation did not observed between changes of leptin levels and BMI, leptin levels and IR. In summary, our data suggest that hypoadiponectinemia in PM may be explained by only IR because the amelioration of whole-body insulin action by 6-month Metformin therapy leads to increase of plasma adiponectin levels; leptin levels did not significantly change after 6-month Metformin therapy.
为了研究脂联素和瘦素在胰岛素抵抗（IR）和肥胖中的相对作用，我们对2型糖尿病（DM2）的肥胖且胰岛素抵抗的绝经后（PM）女性在接受二甲双胍治疗的6个月期间，研究了这些脂肪细胞因子的血浆水平。我们招募了26名年龄在50至67岁（59.7±8.1岁）的PM女性。这些女性的体重指数（BMI）为36.6±1.8kg/m²。在进行基线测量后，开始二甲双胍治疗（每天1700±2550mg）。治疗持续时间为6个月。二甲双胍治疗6个月后脂肪细胞因子的研究结果显示，循环脂联素水平显著升高（19.1±6.0对16.1±3.9ng/ml，p = 0.008），同时BMI显著降低（35.9±1.9对36.6±1.8kg/m²，p = 0.005）以及IR降低（3.05±0.89对3.96±0.70，p<0.001）。脂联素水平变化的幅度与BMI降低的幅度呈正相关（r = 0.4784，p = 0.013）以及与IR降低的幅度呈正相关（r = 0.5779，p = 0.002）。未观察到瘦素水平变化与BMI、瘦素水平与IR之间存在任何显著相关性。总之，我们的数据表明，PM中的低脂联素血症可能仅由IR解释，因为6个月的二甲双胍治疗改善全身胰岛素作用导致血浆脂联素水平升高；6个月的二甲双胍治疗后瘦素水平未显著变化。
